KYMR Quote, Financials, Valuation and Earnings

Amgen has a net margin of -1670.33% compared to Kymera Therapeutics's net margin of 33.28%. Kymera Therapeutics's return on equity of -27.19% beat Amgen's return on equity of 65.35%.

Kymera Therapeutics has a consensus price target of $58.74, signalling upside risk potential of 44%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 22.13%. Given that Kymera Therapeutics has higher upside potential than Amgen, analysts believe Kymera Therapeutics is more attractive than Amgen.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.41% to investors and pays a quarterly dividend of $2.25 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Kymera Therapeutics quarterly revenues are $3.7M, which are smaller than Amgen quarterly revenues of $8.5B. Kymera Therapeutics's net income of -$62.5M is lower than Amgen's net income of $2.8B. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 33.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 32.43x versus 4.38x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -1670.33% compared to Kymera Therapeutics's net margin of --. Kymera Therapeutics's return on equity of -27.19% beat CEL-SCI's return on equity of --.

Kymera Therapeutics has a consensus price target of $58.74, signalling upside risk potential of 44%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 1007.93%. Given that CEL-SCI has higher upside potential than Kymera Therapeutics, analysts believe CEL-SCI is more attractive than Kymera Therapeutics.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $3.7M, which are larger than CEL-SCI quarterly revenues of --. Kymera Therapeutics's net income of -$62.5M is lower than CEL-SCI's net income of -$6.9M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 32.43x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology has a net margin of -1670.33% compared to Kymera Therapeutics's net margin of -73950.52%. Kymera Therapeutics's return on equity of -27.19% beat Vir Biotechnology's return on equity of -35.62%.

Kymera Therapeutics has a consensus price target of $58.74, signalling upside risk potential of 44%. On the other hand Vir Biotechnology has an analysts' consensus of $31.25 which suggests that it could grow by 301.91%. Given that Vir Biotechnology has higher upside potential than Kymera Therapeutics, analysts believe Vir Biotechnology is more attractive than Kymera Therapeutics.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vir Biotechnology has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.783%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Vir Biotechnology pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $3.7M, which are larger than Vir Biotechnology quarterly revenues of $289K. Kymera Therapeutics's net income of -$62.5M is higher than Vir Biotechnology's net income of -$213.7M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Vir Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 32.43x versus 16.06x for Vir Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -1670.33% compared to Kymera Therapeutics's net margin of -36.72%. Kymera Therapeutics's return on equity of -27.19% beat Voyager Therapeutics's return on equity of 9.12%.

Kymera Therapeutics has a consensus price target of $58.74, signalling upside risk potential of 44%. On the other hand Voyager Therapeutics has an analysts' consensus of -- which suggests that it could grow by 198.43%. Given that Voyager Therapeutics has higher upside potential than Kymera Therapeutics, analysts believe Voyager Therapeutics is more attractive than Kymera Therapeutics.

Kymera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.374%.

Kymera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Kymera Therapeutics quarterly revenues are $3.7M, which are smaller than Voyager Therapeutics quarterly revenues of $24.6M. Kymera Therapeutics's net income of -$62.5M is lower than Voyager Therapeutics's net income of -$9M. Notably, Kymera Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 8.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics is 32.43x versus 1.95x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.